-
1
-
-
84864059882
-
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma
-
Azimi, F., Scolyer, R.A., Rumcheva, P., Moncrieff, M., Murali, R., McCarthy, S.W., Saw, R.P., and Thompson, J.F. (2012). Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J. Clin. Oncol. 30, 2678-2683.
-
(2012)
J. Clin. Oncol.
, vol.30
, pp. 2678-2683
-
-
Azimi, F.1
Scolyer, R.A.2
Rumcheva, P.3
Moncrieff, M.4
Murali, R.5
McCarthy, S.W.6
Saw, R.P.7
Thompson, J.F.8
-
2
-
-
0034831138
-
Segmental duplications: organization and impact within the current human genome project assembly
-
Bailey, J.A., Yavor, A.M., Massa, H.F., Trask, B.J., and Eichler, E.E. (2001). Segmental duplications: organization and impact within the current human genome project assembly. Genome Res. 11, 1005-1017.
-
(2001)
Genome Res.
, vol.11
, pp. 1005-1017
-
-
Bailey, J.A.1
Yavor, A.M.2
Massa, H.F.3
Trask, B.J.4
Eichler, E.E.5
-
3
-
-
84861427327
-
Melanoma genome sequencing reveals frequent PREX2 mutations
-
Berger, M.F., Hodis, E., Heffernan, T.P. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
-
(2012)
Nature
, vol.485
, pp. 502-506
-
-
Berger, M.F.1
Hodis, E.2
Heffernan, T.P.3
-
4
-
-
84862903106
-
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
-
Brahmer, J.R., Tykodi, S.S., Chow, L.Q. et al. (2012). Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465.
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 2455-2465
-
-
Brahmer, J.R.1
Tykodi, S.S.2
Chow, L.Q.3
-
5
-
-
61449090474
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma
-
Camacho, L.H., Antonia, S., Sosman, J. et al. (2009). Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27, 1075-1081.
-
(2009)
J. Clin. Oncol.
, vol.27
, pp. 1075-1081
-
-
Camacho, L.H.1
Antonia, S.2
Sosman, J.3
-
6
-
-
0030728259
-
CDKN2A/p16 is inactivated in most melanoma cell lines
-
Castellano, M., Pollock, P.M., Walters, M.K., Sparrow, L.E., Down, L.M., Gabrielli, B.G., Parsons, P.G., and Hayward, N.K. (1997). CDKN2A/p16 is inactivated in most melanoma cell lines. Cancer Res. 57, 4868-4875.
-
(1997)
Cancer Res.
, vol.57
, pp. 4868-4875
-
-
Castellano, M.1
Pollock, P.M.2
Walters, M.K.3
Sparrow, L.E.4
Down, L.M.5
Gabrielli, B.G.6
Parsons, P.G.7
Hayward, N.K.8
-
7
-
-
33646373688
-
Metastatic melanoma to lymph nodes in patients with unknown primary sites
-
Cormier, J.N., Xing, Y., Feng, L., Huang, X., Davidson, L., Gershenwald, J.E., Lee, J.E., Mansfield, P.F., and Ross, M.I. (2006). Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 106, 2012-2020.
-
(2006)
Cancer
, vol.106
, pp. 2012-2020
-
-
Cormier, J.N.1
Xing, Y.2
Feng, L.3
Huang, X.4
Davidson, L.5
Gershenwald, J.E.6
Lee, J.E.7
Mansfield, P.F.8
Ross, M.I.9
-
8
-
-
27844567142
-
Distinct sets of genetic alterations in melanoma
-
Curtin, J.A., Fridlyand, J., Kageshita, T. et al. (2005). Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147.
-
(2005)
N. Engl. J. Med.
, vol.353
, pp. 2135-2147
-
-
Curtin, J.A.1
Fridlyand, J.2
Kageshita, T.3
-
9
-
-
33749021085
-
Somatic activation of KIT in distinct subtypes of melanoma
-
Curtin, J.A., Busam, K., Pinkel, D., and Bastian, B.C. (2006). Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. 24, 4340-4346.
-
(2006)
J. Clin. Oncol.
, vol.24
, pp. 4340-4346
-
-
Curtin, J.A.1
Busam, K.2
Pinkel, D.3
Bastian, B.C.4
-
10
-
-
0000521726
-
Malignant melanoma of unknown primary origin
-
Dasgupta, T., Bowden, L., and Berg, J.W. (1963). Malignant melanoma of unknown primary origin. Surg. Gynecol. Obstet. 117, 341-345.
-
(1963)
Surg. Gynecol. Obstet.
, vol.117
, pp. 341-345
-
-
Dasgupta, T.1
Bowden, L.2
Berg, J.W.3
-
11
-
-
84865839400
-
Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy
-
Dutton-Regester, K., and Hayward, N.K. (2012). Whole genome and exome sequencing of melanoma: a step toward personalized targeted therapy. Adv. Pharmacol. 65, 399-435.
-
(2012)
Adv. Pharmacol.
, vol.65
, pp. 399-435
-
-
Dutton-Regester, K.1
Hayward, N.K.2
-
12
-
-
84857443939
-
Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene
-
Dutton-Regester, K., Aoude, L.G., Nancarrow, D.J. et al. (2012a). Identification of TFG (TRK-fused gene) as a putative metastatic melanoma tumor suppressor gene. Genes Chromosom. Cancer 51, 452-461.
-
(2012)
Genes Chromosom. Cancer
, vol.51
, pp. 452-461
-
-
Dutton-Regester, K.1
Aoude, L.G.2
Nancarrow, D.J.3
-
13
-
-
84861893379
-
A high-throughput panel for identifying clinically relevant mutation profiles in melanoma
-
Dutton-Regester, K., Irwin, D., Hunt, P. et al. (2012b). A high-throughput panel for identifying clinically relevant mutation profiles in melanoma. Mol. Cancer Ther. 11, 888-897.
-
(2012)
Mol. Cancer Ther.
, vol.11
, pp. 888-897
-
-
Dutton-Regester, K.1
Irwin, D.2
Hunt, P.3
-
14
-
-
0013773589
-
Spontaneous regression of cancer
-
Everson, T.C. (1964). Spontaneous regression of cancer. Ann. N. Y. Acad. Sci. 114, 721-735.
-
(1964)
Ann. N. Y. Acad. Sci.
, vol.114
, pp. 721-735
-
-
Everson, T.C.1
-
15
-
-
84861083983
-
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
-
Falchook, G.S., Long, G.V., Kurzrock, R. et al. (2012). Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 379, 1893-1901.
-
(2012)
Lancet
, vol.379
, pp. 1893-1901
-
-
Falchook, G.S.1
Long, G.V.2
Kurzrock, R.3
-
16
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
Flaherty, K.T., Infante, J.R., Daud, A. et al. (2012). Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694-1703.
-
(2012)
N. Engl. J. Med.
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
-
17
-
-
84862702937
-
Genomic characterisation of acral melanoma cell lines
-
Furney, S.J., Turajlic, S., Fenwick, K. et al. (2012). Genomic characterisation of acral melanoma cell lines. Pigment Cell Melanoma Res. 25, 488-492.
-
(2012)
Pigment Cell Melanoma Res.
, vol.25
, pp. 488-492
-
-
Furney, S.J.1
Turajlic, S.2
Fenwick, K.3
-
18
-
-
78649700287
-
Frequent mutation of BAP1 in metastasizing uveal melanomas
-
Harbour, J.W., Onken, M.D., Roberson, E.D., Duan, S., Cao, L., Worley, L.A., Council, M.L., Matatall, K.A., Helms, C., and Bowcock, A.M. (2010). Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330, 1410-1413.
-
(2010)
Science
, vol.330
, pp. 1410-1413
-
-
Harbour, J.W.1
Onken, M.D.2
Roberson, E.D.3
Duan, S.4
Cao, L.5
Worley, L.A.6
Council, M.L.7
Matatall, K.A.8
Helms, C.9
Bowcock, A.M.10
-
19
-
-
84864285704
-
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
-
Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
-
(2012)
Lancet
, vol.380
, pp. 358-365
-
-
Hauschild, A.1
Grob, J.J.2
Demidov, L.V.3
-
20
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi, F.S., O'Day, S.J., McDermott, D.F. et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723.
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
-
21
-
-
84864258996
-
A landscape of driver mutations in melanoma
-
Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
-
(2012)
Cell
, vol.150
, pp. 251-263
-
-
Hodis, E.1
Watson, I.R.2
Kryukov, G.V.3
-
22
-
-
84864722943
-
NRAS mutation status is an independent prognostic factor in metastatic melanoma
-
Jakob, J.A., Bassett Jr, R.L., Ng, C.S. et al. (2012). NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014-4023.
-
(2012)
Cancer
, vol.118
, pp. 4014-4023
-
-
Jakob, J.A.1
Bassett Jr, R.L.2
Ng, C.S.3
-
23
-
-
79953322223
-
Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature
-
Kamposioras, K., Pentheroudakis, G., Pectasides, D., and Pavlidis, N. et al. (2011). Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit. Rev. Oncol. Hematol. 78, 112-126.
-
(2011)
Crit. Rev. Oncol. Hematol.
, vol.78
, pp. 112-126
-
-
Kamposioras, K.1
Pentheroudakis, G.2
Pectasides, D.3
Pavlidis, N.4
-
24
-
-
69949122158
-
VarScan: variant detection in massively parallel sequencing of individual and pooled samples
-
Koboldt, D.C., Chen, K., Wylie, T., Larson, D. E., McLellan, M. D., Mardis, E. R., Weinstock, G. M., Wilson, R.K., and Ding, L. et al. (2009). VarScan: variant detection in massively parallel sequencing of individual and pooled samples. Bioinformatics 25, 2283-2285.
-
(2009)
Bioinformatics
, vol.25
, pp. 2283-2285
-
-
Koboldt, D.C.1
Chen, K.2
Wylie, T.3
Larson, D.E.4
McLellan, M.D.5
Mardis, E.R.6
Weinstock, G.M.7
Wilson, R.K.8
Ding, L.9
-
25
-
-
84865684161
-
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma
-
Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
-
(2012)
Nat. Genet.
, vol.44
, pp. 1006-1014
-
-
Krauthammer, M.1
Kong, Y.2
Ha, B.H.3
-
26
-
-
39149089000
-
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma
-
Lee, C.C., Faries, M.B., Wanek, L.A., and Morton, D.L. et al. (2008). Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma. J. Clin. Oncol. 26, 535-541.
-
(2008)
J. Clin. Oncol.
, vol.26
, pp. 535-541
-
-
Lee, C.C.1
Faries, M.B.2
Wanek, L.A.3
Morton, D.L.4
-
27
-
-
67649884743
-
Fast and accurate short read alignment with Burrows-Wheeler transform
-
Li, H., and Durbin, R. (2009). Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760.
-
(2009)
Bioinformatics
, vol.25
, pp. 1754-1760
-
-
Li, H.1
Durbin, R.2
-
28
-
-
68549104404
-
The Sequence Alignment/Map format and SAMtools
-
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., and Durbin, R. et al. (2009). The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079.
-
(2009)
Bioinformatics
, vol.25
, pp. 2078-2079
-
-
Li, H.1
Handsaker, B.2
Wysoker, A.3
Fennell, T.4
Ruan, J.5
Homer, N.6
Marth, G.7
Abecasis, G.8
Durbin, R.9
-
29
-
-
84978034236
-
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma
-
Long, G.V., Menzies, A.M., Nagrial, A.M., Haydu, L.E., Hamilton, A.L., Mann, G.J., Hughes, T.M., Thompson, J.F., Scolyer, R.A., and Kefford, R.F. et al. (2011). Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol. 29, 1239-1246.
-
(2011)
J. Clin. Oncol.
, vol.29
, pp. 1239-1246
-
-
Long, G.V.1
Menzies, A.M.2
Nagrial, A.M.3
Haydu, L.E.4
Hamilton, A.L.5
Mann, G.J.6
Hughes, T.M.7
Thompson, J.F.8
Scolyer, R.A.9
Kefford, R.F.10
-
30
-
-
84868120907
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial
-
Long, G.V., Trefzer, U., Davies, M.A. et al. (2012). Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 13, 1087-1095.
-
(2012)
Lancet Oncol.
, vol.13
, pp. 1087-1095
-
-
Long, G.V.1
Trefzer, U.2
Davies, M.A.3
-
31
-
-
77955273843
-
IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain
-
Lopez, G.Y., Reitman, Z.J., Solomon, D., Waldman, T., Bigner, D.D., McLendon, R.E., Rosenberg, S.A., Samuels, Y., and Yan, H. (2010). IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. Biochem. Biophys. Res. Commun. 398, 585-587.
-
(2010)
Biochem. Biophys. Res. Commun.
, vol.398
, pp. 585-587
-
-
Lopez, G.Y.1
Reitman, Z.J.2
Solomon, D.3
Waldman, T.4
Bigner, D.D.5
McLendon, R.E.6
Rosenberg, S.A.7
Samuels, Y.8
Yan, H.9
-
32
-
-
84872595484
-
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma
-
Mann, G.J., Pupo, G.M., Campain, A.E et al. (2013). BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J. Invest. Dermatol. 133, 509-517.
-
(2013)
J. Invest. Dermatol.
, vol.133
, pp. 509-517
-
-
Mann, G.J.1
Pupo, G.M.2
Campain, A.E.3
-
33
-
-
70149093912
-
Recurring mutations found by sequencing an acute myeloid leukemia genome
-
Mardis, E.R., Ding, L., Dooling, D.J. et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N. Engl. J. Med. 361, 1058-1066.
-
(2009)
N. Engl. J. Med.
, vol.361
, pp. 1058-1066
-
-
Mardis, E.R.1
Ding, L.2
Dooling, D.J.3
-
34
-
-
84862584008
-
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma
-
Menzies, A.M., Haydu, L.E., Visintin, L., Carlino, M.S., Howle, J.R., Thompson, J.F., Kefford, R.F., Scolyer, R.A., and Long, G.V. (2012). Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin. Cancer Res. 18, 3242-3249.
-
(2012)
Clin. Cancer Res.
, vol.18
, pp. 3242-3249
-
-
Menzies, A.M.1
Haydu, L.E.2
Visintin, L.3
Carlino, M.S.4
Howle, J.R.5
Thompson, J.F.6
Kefford, R.F.7
Scolyer, R.A.8
Long, G.V.9
-
35
-
-
84856268319
-
Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma
-
Nikolaev, S.I., Rimoldi, D., Iseli, C. et al. (2012). Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat. Genet. 44, 133-139.
-
(2012)
Nat. Genet.
, vol.44
, pp. 133-139
-
-
Nikolaev, S.I.1
Rimoldi, D.2
Iseli, C.3
-
36
-
-
2942533921
-
Microarray expression profiling in melanoma reveals a BRAF mutation signature
-
Pavey, S., Johansson, P., Packer, L. et al. (2004). Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23, 4060-4067.
-
(2004)
Oncogene
, vol.23
, pp. 4060-4067
-
-
Pavey, S.1
Johansson, P.2
Packer, L.3
-
37
-
-
74449093973
-
A comprehensive catalogue of somatic mutations from a human cancer genome
-
Pleasance, E.D., Cheetham, R.K., Stephens, P.J. et al. (2010). A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 463, 191-196.
-
(2010)
Nature
, vol.463
, pp. 191-196
-
-
Pleasance, E.D.1
Cheetham, R.K.2
Stephens, P.J.3
-
38
-
-
82955233515
-
Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site
-
Prens, S.P., van der Ploeg, A.P., van Akkooi, A.C., van Montfort, C.A., van Geel, A.N., de Wilt, J.H., Eggermont, A.M., and Verhoef, C. (2011). Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site. Ann. Surg. Oncol. 18, 3586-3592.
-
(2011)
Ann. Surg. Oncol.
, vol.18
, pp. 3586-3592
-
-
Prens, S.P.1
van der Ploeg, A.P.2
van Akkooi, A.C.3
van Montfort, C.A.4
van Geel, A.N.5
de Wilt, J.H.6
Eggermont, A.M.7
Verhoef, C.8
-
39
-
-
0017344834
-
Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance
-
Ridolfi, R.L., Rosen, P.P., and Thaler, H. (1977). Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance. Cancer 39, 164-171.
-
(1977)
Cancer
, vol.39
, pp. 164-171
-
-
Ridolfi, R.L.1
Rosen, P.P.2
Thaler, H.3
-
40
-
-
0032589240
-
Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells
-
Rizos, H., Darmanian, A.P., Indsto, J.O., Shannon, J.A., Kefford, R.F., and Mann, G.J. (1999). Multiple abnormalities of the p16INK4a-pRb regulatory pathway in cultured melanoma cells. Melanoma Res. 9, 10-19.
-
(1999)
Melanoma Res.
, vol.9
, pp. 10-19
-
-
Rizos, H.1
Darmanian, A.P.2
Indsto, J.O.3
Shannon, J.A.4
Kefford, R.F.5
Mann, G.J.6
-
41
-
-
0023136996
-
Malignant melanoma primary in lymph node. The case of the missing link
-
Shenoy, B.V., Fort 3rd, L., and Benjamin, S.P. (1987). Malignant melanoma primary in lymph node. The case of the missing link. Am. J. Surg. Pathol. 11, 140-146.
-
(1987)
Am. J. Surg. Pathol.
, vol.11
, pp. 140-146
-
-
Shenoy, B.V.1
Fort III, L.2
Benjamin, S.P.3
-
42
-
-
79952769109
-
Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation
-
Shibata, T., Kokubu, A., Miyamoto, M., Sasajima, Y., and Yamazaki, N. (2011). Mutant IDH1 confers an in vivo growth in a melanoma cell line with BRAF mutation. Am. J. Pathol. 178, 1395-1402.
-
(2011)
Am. J. Pathol.
, vol.178
, pp. 1395-1402
-
-
Shibata, T.1
Kokubu, A.2
Miyamoto, M.3
Sasajima, Y.4
Yamazaki, N.5
-
43
-
-
0013815469
-
Spontaneous regression of primary malignant melanomas with regional metastases
-
Smith Jr, J.L., and Stehlin Jr, J.S. (1965). Spontaneous regression of primary malignant melanomas with regional metastases. Cancer 18, 1399-1415.
-
(1965)
Cancer
, vol.18
, pp. 1399-1415
-
-
Smith Jr, J.L.1
Stehlin Jr, J.S.2
-
44
-
-
34047258036
-
Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays
-
Stark, M., and Hayward, N. (2007). Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 67, 2632-2642.
-
(2007)
Cancer Res.
, vol.67
, pp. 2632-2642
-
-
Stark, M.1
Hayward, N.2
-
45
-
-
84856273432
-
Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing
-
Stark, M.S., Woods, S.L., Gartside, M.G. et al. (2012). Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing. Nat. Genet. 44, 165-169.
-
(2012)
Nat. Genet.
, vol.44
, pp. 165-169
-
-
Stark, M.S.1
Woods, S.L.2
Gartside, M.G.3
-
46
-
-
34547697828
-
Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells
-
Stefansson, B., and Brautigan, D.L. (2007). Protein phosphatase PP6 N terminal domain restricts G1 to S phase progression in human cancer cells. Cell Cycle 6, 1386-1392.
-
(2007)
Cell Cycle
, vol.6
, pp. 1386-1392
-
-
Stefansson, B.1
Brautigan, D.L.2
-
47
-
-
84862859820
-
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
-
Topalian, S.L., Hodi, F.S., Brahmer, J.R. et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
-
(2012)
N. Engl. J. Med.
, vol.366
, pp. 2443-2454
-
-
Topalian, S.L.1
Hodi, F.S.2
Brahmer, J.R.3
-
48
-
-
80255132732
-
Extensive screening for primary tumor is redundant in melanoma of unknown primary
-
Tos, T., Klyver, H., and Drzewiecki, K.T. (2011). Extensive screening for primary tumor is redundant in melanoma of unknown primary. J. Surg. Oncol. 104, 724-727.
-
(2011)
J. Surg. Oncol.
, vol.104
, pp. 724-727
-
-
Tos, T.1
Klyver, H.2
Drzewiecki, K.T.3
-
49
-
-
84863393606
-
Whole genome sequencing of matched primary and metastatic acral melanomas
-
Turajlic, S., Furney, S.J., Lambros, M.B. et al. (2012). Whole genome sequencing of matched primary and metastatic acral melanomas. Genome Res. 22, 196-207.
-
(2012)
Genome Res.
, vol.22
, pp. 196-207
-
-
Turajlic, S.1
Furney, S.J.2
Lambros, M.B.3
-
50
-
-
59049107421
-
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
-
Van Raamsdonk, C.D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O'Brien, J.M., Simpson, E.M., Barsh, G.S., and Bastian, B.C. (2009). Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457, 599-602.
-
(2009)
Nature
, vol.457
, pp. 599-602
-
-
Van Raamsdonk, C.D.1
Bezrookove, V.2
Green, G.3
Bauer, J.4
Gaugler, L.5
O'Brien, J.M.6
Simpson, E.M.7
Barsh, G.S.8
Bastian, B.C.9
-
51
-
-
78651446131
-
Mutations in GNA11 in uveal melanoma
-
Van Raamsdonk, C.D., Griewank, K.G., Crosby, M.B. et al. (2010). Mutations in GNA11 in uveal melanoma. N. Engl. J. Med. 363, 2191-2199.
-
(2010)
N. Engl. J. Med.
, vol.363
, pp. 2191-2199
-
-
Van Raamsdonk, C.D.1
Griewank, K.G.2
Crosby, M.B.3
-
52
-
-
77956534324
-
ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
-
Wang, K., Li, M., and Hakonarson, H. (2010). ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164.
-
(2010)
Nucleic Acids Res.
, vol.38
-
-
Wang, K.1
Li, M.2
Hakonarson, H.3
-
53
-
-
85027946522
-
Exome sequencing identifies GRIN2A as frequently mutated in melanoma
-
Wei, X., Walia, V., Lin, J.C. et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nat. Genet. 43, 442-446.
-
(2011)
Nat. Genet.
, vol.43
, pp. 442-446
-
-
Wei, X.1
Walia, V.2
Lin, J.C.3
-
54
-
-
60849115270
-
IDH1 and IDH2 mutations in gliomas
-
Yan, H., Parsons, D.W., Jin, G. et al. (2009). IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765-773.
-
(2009)
N. Engl. J. Med.
, vol.360
, pp. 765-773
-
-
Yan, H.1
Parsons, D.W.2
Jin, G.3
|